Philip Morris
Research Plan
Fields
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Type
- REPT, OTHER REPORT
- CHAR, CHART/GRAPH
- Named Organization
- Cetus
- Standard Oil
- Request
- Stmn/R1-004
- Stmn/R1-150
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Litigation
- Stmn/Produced
- Characteristic
- CONF, CONFIDENTIAL
- MARG, MARGINALIA
- Site
- R37
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- xfo74e00
Document Images
JJ'`vC,, a ~}y
~i.. ...:~~ .... .tr.'Z"~~ I". C.:J:. _..-1.ar..f~i3A.~..~; l..:f.i'.~~~.f~'."i ~... ...~...
.:f~>.`':..'~i . .. ~_.. _ .... ~'~KT!
r'SSf wd :i-. .._..," .",_ /JSt
w~~.._? _- . ~'..~~`~+.,,',.' ..,.. `::.i3~ .... itis~.b~v'~`~~ -~~f~a . ~i3.',i,'~s,'~`lt,~'
r.tA;.'1 , -rc, . _ ~ - 1"_,... ~*' _ ... . ;.~ /. i'?' .
.. , . i.. .... . .... .~ ~':}'..,. ~r:. .'~- ,.. , ..~~t~T t'. L)'..f1~..~~ _. .:+.~ .. _
:~i v,s b..~3 T - r... r-_ ~t.-.t n', 1'_.7. F n ... L.. f'i ~^- . _
_...t~,;,_ ..~s._.._r s,:_,:_ l.t.f ,... .,.r;,...~ v...- .~° s;o.~ ..._...__. s. __.,;~~ :.~._ .
. _ ---- ..._ _ :e'r ,.
t. -
........~.~.r.:'7i'.i ~-~.~!
f T ._~:: ; ...~ ~~~ .~., wJ~. t' a ~' ~ ~. _ .... :, :~i's~:
b '. 1:w ~r~3'? `~.oti.:;.. :c j.~I -d
'
dYt~.C~..f:"t# 3:]~ ,F+~'j..; -'-.
`r __~; :'}_...,. 1 ' .."~?~3t~
5 ?~ r ~:., ~~ X 4 ~ 5.r"~i:E ~ ~ ti~ '~ tC"'7 _.. ,..0'a `~~+ ,'1. 3 : _. : : I~ .. . _ ., :
yY:
..ti . . a~
" ., -,.-. ..
~
_^.
~,
si~,3'S ~ h '~ a,~ "t~'f ,.,:! ~' ~'. ~ ~ -s 7~ 'x .Ct',~s~~~: Tt"~~= ?'I ~. ~~ :,' r v' ~
,;_1-+ L` ` _ fi'
. ~~° 1~' ., Q ^S 9t( ~.i. ~',~~
-'~:V+~ {2~v _.I ,+~?1i "S,".; .".b.."'ifi.. ,'~.G.`,i '..}C~. ~»..£ ~t iyP_~'fS.''~~...~Q~."~"
~~.i ~~.1~ :)~ _. _:~~::#~7` #'3,~_~~'. ~~'. a4~E
.a. . :-~"I'r !.. ~~~'~r ~ !''.:~'?-z. ~i: .; -:~`.L fi,...._ . =u ,N~-~ ...i;~_: _~-: ~~ 0~ _.
-.. ,~"-.-. , . Z, .. ;.:~ ;.,t'~.
' ~' .~"~X:'...a... ~'~ . i`E:.t..'r'rd, ~;5 ..._ ?_):.'aY a.:.e ~U. -,'~~ 3~' _., Q , . _.._ ..
.. . _ . , ~ f.:i~!I
-~ . .. . . . . -~ . ~J . \ y.
~ . .'1 ~'~ ".1~. . s r .':~ - j -':J ~ ~ ' ~~`1 .. "' ~fi - . /. _O .. _ .: . ~`.. . `r?'i ,
v':~~.
. . _ i. .. »1 ,. ~l ~Y~
1._.. r
.1~.: oGJQj
._., _.-~~
,:
'G
~.,. ~a .~y
.. . ... - . .. . . , .. ~rr.
~.~~ ~fi~ 0{`~
' , , . ., ,. . Q~,o ~a. os~. . ... ,. ... .. . . ..
GO~ cti~ G
GO
O
'6oG'$~~
..:-f .~.I~t~in_ _ . ' .... . nt.vl .'!~%:r. . - : :.-'~:y:.S.'J5?i=~'S.Yi.~

SCHEDULE OFEXPENDITURES FOR CETUS PROPRIETARY
RESEARCH PROGRAMS
($000)
C)
- -A
in.sthe plan.
a~ :~e~,:w:n~~w;~a.G...:r:~,,.... ~i~~~:~:
Cash IN
Equity (received by July 78)
Interest (7% on avg. balance)
Total IN
Cash OUT
RMR
Capital expenditures
Operating expenditures
6000
350
6350
FY 80 FY 81
210
,t210
o
tih ~ =
ti
o{
964 o' 2001)(1
200 G'rv fi 300=
ti
-1K Ll
C~
FERM/ENZYME TECHNOLOGY ~ 52
Capital expenditures 525 41, 750
Operating expenditure O~ ~5Q"
INSTRUMENTATION
1OU'
Capital expenditures' ¢,~' a c250 500~
~ ~
Operating expenditures ;;'o~` 250 275
CC3` ~J~o JQ 2339 2175
o-
~~
`~
CASH BALANCE
Total IN 0 6350 210
Total OUT o~{~{' <2339> <2175>
Cash at end of FiscalkYear 4011 2046
GO~~1 G
6o 1,'~~ GZ' ~
a~°
0 ~ . tifi ati
Note:~~hi's-~`oes not affect the overall projected'cash flow presented

,~
~.
o,
oA
V~J,10
41
~a. 0~.tA 0
1~ ~.ro Aas S
r)~
`Y~
o
~J
~aA
~ a Qo
Of`lfrd, o~ ~ ,ro
~ Cr
Cl'Q ~a Atrp ~
r o
J s O'o~qs J~a~
~ko 4a~0
o~
ak"`~aPj 40
i ~ooAP'~~I~ p

CAPITAL EXPENDITURES FOR CETUS PROPRIETARY
RESEARCH PROGRAMS
RMR
-Operating needs/Replacement
Leasehold Imp/Replacement
_PIA Addition
Lab Aeiciition
Equipment Additions
~'..' P
Equipment
3
E. Microscope
Lab Equipment
FERMENTATION/ENZYME TECHNOLOGY
Leasehold Imp/Replacement
Process Additions
Equipment Additions '
' Process Equipment
~ DOTAL FERM/ENZYME TECHNOLOGY
INSTRUMENTATION
Equipment Additions
New Proprietary Equipment,~
TOTAL INSTRUMENTATION
O
c~L fi4 '~~
Total Capital Expenditures for o
75 . ., ~`100 100
~v
2
a
"
694 ~
e~ 00 4,Q
2 0
Q
^Iv _ _1R77
:. tti
.Cetus Proprietary Research Programs 270 1469 1450
~
GG-C,
G ?S ~
o ..tifi~'
'Capital Expendituresor -
Client Funded Operations
TOTAL CAPITAL EXPENDITURES
1100
* Only the P and RMR lab additions were included. Other FY 78 expenditures are 3 small and will be
absorbed into client funded operations.
These numb.ers tie directly to the capital expenditures outlined in the three
year operating plan.
Cte:
,
o
.
100 ,oe ,
k
~ ..
. 100 .,° q

~
A4o tor~~
4ot AJ
?b,f,~~ ~A~JOo~
~P r p ~? r
OJ . a,pr lq~ ~aJ
a
Q o 4 S,
r~~
~(t 'rUp 'b a ,~p
o p4~ o~ ao ~o
. `.
Y0 4~p s4o
0 S 4'~ .rvs 0 °~a a a
~~
4J;,411, °A a~04'T
o trr r~
J4at~`pa~r 4'o
oo~`~~Gl~

OPERATING EXPENDITURES FOR CETUS PROPRIETARY
~ -LRMR
Total Expenditures: RMR
RESEARCH PROJECTS
"Less: Amt. charged to client projects
Amt. to proprietary research
FERMENTATION/ENZYME TECHNOLOGY
Total Expenditures: Biology
Less: Amt. charged to client projects <150> V<i00> 400>
Amt. allocated to Ferny/Enz. Technology ' 300 Z,450 ~ti~00
amt. to proprietary research i..', ,! , ti150 ~)'.;~o` 150 IV 200
INSTRUMENTATION
Less: Amt. charged'to client projects $ ~700> <125> <180>
Amt. to proprietary research t~t250 275 300
Total Expenditures: Instrumentation ~~_ -
350~- 400 480
(
Notes:
V c==
Ltia ~}~
r
825
1) These numbers tie directly t
o theprojected Corporate Income Statement
(page 2 financial attachments) outlined in the three year plan.
2) These are direct, incremental costs.only. No amounts have been added for
depreciation or otherscorporate overheads.
``
`
G
ti~; ` o`:, o~
.
S fi
4so4~`~' o~~ .
Gflfi ~~' a~~
t`
GO~ 110
Z0G. {1~'~ ,~l
2
($000)
FY 79 FY 80
750 1250
<550> <950>
200 300
2610 34001` 4Q00

oi~~
S 4%r, '
O,roA °l°
?a. ~°r~ ~o
p~ ~ .
a
Q
4r
°~
'ro
sr a `~J
Y° -43h
f ~! :i - ),
o J
dJ
J r 4
4r o 090 ,ro
Ooo do
OQ, TaA~ riA
JS oJiy ao 0
tr~ o
pr
o °
~,r
-
a 4r ?.;i a
~~~a
N rep
p
J°A`'~~~P~
ja
?~,
